PubMed:9796963
Annnotations
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 37-50 | cell_type | denotes | T lymphocytes |
| T2 | 130-138 | protein | denotes | cytokine |
| T3 | 195-222 | protein | denotes | CD3/T-cell antigen receptor |
| T4 | 224-227 | protein | denotes | TCR |
| T5 | 268-281 | cell_type | denotes | T lymphocytes |
| T6 | 359-366 | protein | denotes | TCRzeta |
| T7 | 371-379 | protein | denotes | p56(lck) |
| T8 | 409-412 | protein | denotes | TCR |
| T9 | 449-507 | protein | denotes | RelA containing nuclear factor kappaB (NFkappaB) complexes |
| T10 | 562-569 | cell_type | denotes | T cells |
| T11 | 843-850 | protein | denotes | TCRzeta |
| T12 | 852-860 | protein | denotes | p56(lck) |
| T13 | 889-897 | protein | denotes | NFkappaB |
| T14 | 899-912 | cell_type | denotes | T lymphocytes |
| T15 | 1002-1010 | protein | denotes | cytokine |
| T16 | 1020-1038 | protein | denotes | interleukin (IL)-2 |
| T17 | 1040-1049 | protein | denotes | IFN alpha |
| T18 | 1134-1141 | protein | denotes | TCRzeta |
| T19 | 1146-1154 | protein | denotes | p56(lck) |
| T20 | 1512-1520 | protein | denotes | NFkappaB |
| T21 | 1608-1615 | cell_type | denotes | T cells |
| T22 | 1660-1688 | protein | denotes | anti-CD3 monoclonal antibody |
| T23 | 1734-1742 | protein | denotes | cytokine |
| T24 | 1777-1784 | protein | denotes | TCRzeta |
| T25 | 1789-1797 | protein | denotes | p56(lck) |
| T26 | 1819-1843 | cell_type | denotes | peripheral blood T cells |
| T27 | 2056-2063 | protein | denotes | TCRzeta |
| T28 | 2080-2088 | protein | denotes | p56(lck) |
| T29 | 2109-2119 | protein | denotes | CD3epsilon |
| T30 | 2205-2214 | protein | denotes | IFN alpha |
| T31 | 2249-2256 | protein | denotes | TCRzeta |
| T32 | 2360-2367 | protein | denotes | TCRzeta |
| T33 | 2371-2379 | protein | denotes | p56(lck) |
| T34 | 2440-2447 | protein | denotes | TCRzeta |
| T35 | 2528-2536 | protein | denotes | NFkappaB |
| T36 | 2614-2642 | protein | denotes | anti-CD3 monoclonal antibody |
| T37 | 2764-2772 | protein | denotes | NFkappaB |
| T38 | 2776-2800 | cell_type | denotes | peripheral blood T cells |
| T39 | 2822-2830 | protein | denotes | cytokine |
| T40 | 2889-2897 | protein | denotes | NFkappaB |
| T41 | 2958-2966 | protein | denotes | NFkappaB |
| T42 | 3008-3015 | protein | denotes | TCRzeta |
| T43 | 3061-3068 | protein | denotes | TCRzeta |
| T44 | 3098-3104 | protein | denotes | kappaB |
| T45 | 3179-3203 | cell_type | denotes | peripheral blood T cells |
| T46 | 3212-3219 | protein | denotes | TCRzeta |
| T47 | 3224-3232 | protein | denotes | p56(lck) |
| T48 | 3275-3303 | protein | denotes | TCRzeta associated molecules |
| T49 | 3338-3346 | protein | denotes | cytokine |
| T50 | 3385-3393 | protein | denotes | NFkappaB |
| T51 | 3472-3481 | protein | denotes | IFN alpha |
| T52 | 3518-3526 | protein | denotes | NFkappaB |
| T53 | 3587-3624 | DNA | denotes | TCRzeta-associated signaling elements |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-147 | Sentence | denotes | Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. |
| S2 | 148-333 | Sentence | denotes | Studies have demonstrated abnormalities of the CD3/T-cell antigen receptor (TCR) and pathways of signal transduction in T lymphocytes from animals and patients with advanced malignancy. |
| S3 | 334-524 | Sentence | denotes | Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted. |
| S4 | 525-675 | Sentence | denotes | These defects have been described in T cells from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer. |
| S5 | 676-796 | Sentence | denotes | Preliminary observations also indicate possible correlation with clinical variables such as stage in selected instances. |
| S6 | 797-1098 | Sentence | denotes | To further characterize altered expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals. |
| S7 | 1099-1245 | Sentence | denotes | In 29 of these patients, levels of TCRzeta and p56(lck) were determined by Western blots of T-cell lysates and semiquantitated using densitometry. |
| S8 | 1246-1411 | Sentence | denotes | Relative levels were then correlated with a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others. |
| S9 | 1412-1689 | Sentence | denotes | In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody. |
| S10 | 1690-1776 | Sentence | denotes | Changes in these signaling molecules during cytokine treatment were also investigated. |
| S11 | 1777-1977 | Sentence | denotes | TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively. |
| S12 | 1978-2174 | Sentence | denotes | When levels were semiquantitated using densitometry, significant decreases of TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were found. |
| S13 | 2175-2343 | Sentence | denotes | In patients treated with IL-2/IFN alpha-based therapy, relative levels of TCRzeta increased significantly (P = 0.002) on day 15 of cycle one compared with the baseline. |
| S14 | 2344-2518 | Sentence | denotes | Correlations of TCRzeta or p56(lck) levels with response or disease variables, except for lower TCRzeta levels (P < 0.001) in the presence of bone metastases, were not found. |
| S15 | 2519-2749 | Sentence | denotes | Abnormal NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort. |
| S16 | 2750-2924 | Sentence | denotes | Activation of NFkappaB in peripheral blood T cells was inducible during cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy. |
| S17 | 2925-3131 | Sentence | denotes | Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible. |
| S18 | 3132-3361 | Sentence | denotes | In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy. |
| S19 | 3362-3498 | Sentence | denotes | Abnormal activation of NFkappaB is also present in >50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment. |
| S20 | 3499-3625 | Sentence | denotes | This alteration in NFkappaB activation occurred in the presence of normal expression of TCRzeta-associated signaling elements. |
| S21 | 3626-3686 | Sentence | denotes | The clinical significance of these findings remains unclear. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 70-94 | NP | denotes | advanced renal carcinoma |
| C2 | 130-146 | NP | denotes | cytokine therapy |
| C4 | 359-366 | NP | denotes | TCRzeta |
| C5 | 371-379 | NP | denotes | p56(lck) |
| C3 | 359-379 | NP | denotes | TCRzeta and p56(lck) |
| C6 | 380-384 | NP | denotes | that |
| C7 | 843-850 | NP | denotes | TCRzeta |
| C8 | 852-860 | NP | denotes | p56(lck) |
| C10 | 889-897 | NP | denotes | NFkappaB |
| C9 | 866-897 | NP | denotes | impaired activation of NFkappaB |
| C11 | 899-912 | NP | denotes | T lymphocytes |
| C12 | 932-952 | NP | denotes | 65 patients with RCC |
| C13 | 970-974 | NP | denotes | whom |
| C15 | 1108-1122 | NP | denotes | these patients |
| C14 | 1102-1122 | NP | denotes | 29 of these patients |
| C18 | 1134-1141 | NP | denotes | TCRzeta |
| C19 | 1146-1154 | NP | denotes | p56(lck) |
| C17 | 1134-1154 | NP | denotes | TCRzeta and p56(lck) |
| C16 | 1124-1154 | NP | denotes | levels of TCRzeta and p56(lck) |
| C20 | 1232-1244 | NP | denotes | densitometry |
| C21 | 1415-1484 | NP | denotes | another group of 28 patients (three individuals from the first group) |
| C22 | 1503-1531 | NP | denotes | abnormal NFkappaB activation |
| C23 | 1608-1615 | NP | denotes | T cells |
| C25 | 1777-1784 | NP | denotes | TCRzeta |
| C26 | 1789-1797 | NP | denotes | p56(lck) |
| C24 | 1777-1797 | NP | denotes | TCRzeta and p56(lck) |
| C27 | 1853-1864 | NP | denotes | 29 patients |
| C28 | 2017-2029 | NP | denotes | densitometry |
| C29 | 2056-2063 | NP | denotes | TCRzeta |
| C30 | 2080-2088 | NP | denotes | p56(lck) |
| C31 | 2249-2256 | NP | denotes | TCRzeta |
| C32 | 2360-2386 | NP | denotes | TCRzeta or p56(lck) levels |
| C33 | 2663-2671 | NP | denotes | patients |
| C34 | 2764-2772 | NP | denotes | NFkappaB |
| C35 | 2776-2800 | NP | denotes | peripheral blood T cells |
| C36 | 2842-2865 | NP | denotes | four of six individuals |
| C37 | 2866-2869 | NP | denotes | who |
| C38 | 2916-2923 | NP | denotes | therapy |
| C40 | 2958-2966 | NP | denotes | NFkappaB |
| C39 | 2935-2966 | NP | denotes | impaired activation of NFkappaB |
| C41 | 3165-3177 | NP | denotes | advanced RCC |
| C42 | 3179-3203 | NP | denotes | peripheral blood T cells |
| C44 | 3212-3219 | NP | denotes | TCRzeta |
| C45 | 3224-3232 | NP | denotes | p56(lck) |
| C43 | 3212-3232 | NP | denotes | TCRzeta and p56(lck) |
| C46 | 3338-3360 | NP | denotes | cytokine-based therapy |
| C48 | 3385-3393 | NP | denotes | NFkappaB |
| C47 | 3362-3393 | NP | denotes | Abnormal activation of NFkappaB |
| R1 | C6 | C3 | coref-relat | that,TCRzeta and p56(lck) |
| R2 | C7 | C4 | coref-ident | TCRzeta,TCRzeta |
| R3 | C8 | C5 | coref-ident | p56(lck),p56(lck) |
| R4 | C13 | C12 | coref-pron | whom,65 patients with RCC |
| R5 | C15 | C12 | coref-ident | these patients,65 patients with RCC |
| R6 | C18 | C7 | coref-ident | TCRzeta,TCRzeta |
| R7 | C19 | C8 | coref-ident | p56(lck),p56(lck) |
| R8 | C17 | C3 | coref-ident | TCRzeta and p56(lck),TCRzeta and p56(lck) |
| R9 | C23 | C11 | coref-ident | T cells,T lymphocytes |
| R10 | C25 | C18 | coref-ident | TCRzeta,TCRzeta |
| R11 | C26 | C19 | coref-ident | p56(lck),p56(lck) |
| R12 | C24 | C17 | coref-ident | TCRzeta and p56(lck),TCRzeta and p56(lck) |
| R13 | C27 | C14 | coref-ident | 29 patients,29 of these patients |
| R14 | C28 | C20 | coref-ident | densitometry,densitometry |
| R15 | C29 | C25 | coref-ident | TCRzeta,TCRzeta |
| R16 | C30 | C26 | coref-ident | p56(lck),p56(lck) |
| R17 | C31 | C29 | coref-ident | TCRzeta,TCRzeta |
| R18 | C32 | C16 | coref-ident | TCRzeta or p56(lck) levels,levels of TCRzeta and p56(lck) |
| R19 | C33 | C21 | coref-ident | patients,another group of 28 patients (three individuals from the first group) |
| R20 | C34 | C10 | coref-ident | NFkappaB,NFkappaB |
| R21 | C37 | C36 | coref-relat | who,four of six individuals |
| R22 | C38 | C2 | coref-ident | therapy,cytokine therapy |
| R23 | C40 | C34 | coref-ident | NFkappaB,NFkappaB |
| R24 | C39 | C9 | coref-ident | impaired activation of NFkappaB,impaired activation of NFkappaB |
| R25 | C41 | C1 | coref-ident | advanced RCC,advanced renal carcinoma |
| R26 | C42 | C35 | coref-ident | peripheral blood T cells,peripheral blood T cells |
| R27 | C44 | C31 | coref-ident | TCRzeta,TCRzeta |
| R28 | C45 | C30 | coref-ident | p56(lck),p56(lck) |
| R29 | C43 | C24 | coref-ident | TCRzeta and p56(lck),TCRzeta and p56(lck) |
| R30 | C46 | C38 | coref-ident | cytokine-based therapy,therapy |
| R31 | C48 | C40 | coref-ident | NFkappaB,NFkappaB |
| R32 | C47 | C22 | coref-ident | Abnormal activation of NFkappaB,abnormal NFkappaB activation |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-33 | other_name | denotes | Signal transduction abnormalities |
| T2 | 37-50 | cell_type | denotes | T lymphocytes |
| T3 | 56-64 | multi_cell | denotes | patients |
| T4 | 79-94 | other_name | denotes | renal carcinoma |
| T5 | 130-138 | protein_family_or_group | denotes | cytokine |
| T6 | 195-222 | protein_molecule | denotes | CD3/T-cell antigen receptor |
| T7 | 224-227 | protein_molecule | denotes | TCR |
| T8 | 245-264 | other_name | denotes | signal transduction |
| T9 | 268-281 | cell_type | denotes | T lymphocytes |
| T10 | 299-307 | multi_cell | denotes | patients |
| T11 | 313-332 | other_name | denotes | advanced malignancy |
| T12 | 359-366 | protein_molecule | denotes | TCRzeta |
| T13 | 371-379 | protein_molecule | denotes | p56(lck) |
| T14 | 409-412 | protein_molecule | denotes | TCR |
| T15 | 449-453 | protein_subunit | denotes | RelA |
| T16 | 488-496 | protein_complex | denotes | NFkappaB |
| T17 | 562-569 | cell_type | denotes | T cells |
| T18 | 575-583 | multi_cell | denotes | patients |
| T19 | 589-607 | other_name | denotes | malignant melanoma |
| T20 | 609-629 | other_name | denotes | renal cell carcinoma |
| T21 | 631-634 | other_name | denotes | RCC |
| T22 | 637-651 | other_name | denotes | ovarian cancer |
| T23 | 657-674 | other_name | denotes | colorectal cancer |
| T24 | 843-850 | protein_molecule | denotes | TCRzeta |
| T25 | 852-860 | protein_molecule | denotes | p56(lck) |
| T26 | 889-897 | protein_complex | denotes | NFkappaB |
| T27 | 899-912 | cell_type | denotes | T lymphocytes |
| T28 | 935-943 | multi_cell | denotes | patients |
| T29 | 949-952 | other_name | denotes | RCC |
| T30 | 1002-1010 | protein_family_or_group | denotes | cytokine |
| T31 | 1020-1038 | protein_molecule | denotes | interleukin (IL)-2 |
| T32 | 1040-1049 | protein_molecule | denotes | IFN alpha |
| T33 | 1114-1122 | multi_cell | denotes | patients |
| T34 | 1134-1141 | protein_molecule | denotes | TCRzeta |
| T35 | 1146-1154 | protein_molecule | denotes | p56(lck) |
| T36 | 1174-1187 | other_name | denotes | Western blots |
| T37 | 1191-1205 | other_organic_compound | denotes | T-cell lysates |
| T38 | 1232-1244 | other_name | denotes | densitometry |
| T39 | 1329-1348 | other_name | denotes | response to therapy |
| T40 | 1350-1368 | other_name | denotes | performance status |
| T41 | 1380-1393 | other_name | denotes | disease sites |
| T42 | 1435-1443 | multi_cell | denotes | patients |
| T43 | 1490-1511 | other_name | denotes | frequency of abnormal |
| T44 | 1512-1520 | protein_complex | denotes | NFkappaB |
| T45 | 1608-1615 | cell_type | denotes | T cells |
| T46 | 1621-1656 | other_organic_compound | denotes | phorbol myristate acetate/ionomycin |
| T47 | 1660-1688 | protein_family_or_group | denotes | anti-CD3 monoclonal antibody |
| T48 | 1734-1742 | protein_family_or_group | denotes | cytokine |
| T49 | 1777-1784 | protein_molecule | denotes | TCRzeta |
| T50 | 1789-1797 | protein_molecule | denotes | p56(lck) |
| T51 | 1819-1843 | cell_type | denotes | peripheral blood T cells |
| T52 | 1856-1864 | multi_cell | denotes | patients |
| T53 | 2017-2029 | other_name | denotes | densitometry |
| T54 | 2056-2063 | protein_molecule | denotes | TCRzeta |
| T55 | 2080-2088 | protein_molecule | denotes | p56(lck) |
| T56 | 2109-2119 | protein_molecule | denotes | CD3epsilon |
| T57 | 2178-2186 | multi_cell | denotes | patients |
| T58 | 2205-2214 | protein_molecule | denotes | IFN alpha |
| T59 | 2249-2256 | protein_molecule | denotes | TCRzeta |
| T60 | 2360-2367 | protein_molecule | denotes | TCRzeta |
| T61 | 2371-2379 | protein_molecule | denotes | p56(lck) |
| T62 | 2440-2447 | protein_molecule | denotes | TCRzeta |
| T63 | 2486-2501 | tissue | denotes | bone metastases |
| T64 | 2519-2527 | other_name | denotes | Abnormal |
| T65 | 2528-2536 | protein_complex | denotes | NFkappaB |
| T66 | 2571-2606 | other_organic_compound | denotes | phorbol myristate acetate/ionomycin |
| T67 | 2614-2642 | protein_family_or_group | denotes | anti-CD3 monoclonal antibody |
| T68 | 2663-2671 | multi_cell | denotes | patients |
| T69 | 2764-2772 | protein_complex | denotes | NFkappaB |
| T70 | 2776-2800 | cell_type | denotes | peripheral blood T cells |
| T71 | 2822-2830 | protein_family_or_group | denotes | cytokine |
| T72 | 2889-2897 | protein_complex | denotes | NFkappaB |
| T73 | 2958-2966 | protein_complex | denotes | NFkappaB |
| T74 | 3008-3015 | protein_molecule | denotes | TCRzeta |
| T75 | 3044-3052 | multi_cell | denotes | patients |
| T76 | 3054-3060 | other_name | denotes | normal |
| T77 | 3061-3068 | protein_molecule | denotes | TCRzeta |
| T78 | 3098-3104 | protein_molecule | denotes | kappaB |
| T79 | 3151-3159 | multi_cell | denotes | patients |
| T80 | 3174-3177 | other_name | denotes | RCC |
| T81 | 3179-3203 | cell_type | denotes | peripheral blood T cells |
| T82 | 3212-3219 | protein_molecule | denotes | TCRzeta |
| T83 | 3224-3232 | protein_molecule | denotes | p56(lck) |
| T84 | 3275-3282 | protein_molecule | denotes | TCRzeta |
| T85 | 3338-3346 | protein_family_or_group | denotes | cytokine |
| T86 | 3385-3393 | protein_complex | denotes | NFkappaB |
| T87 | 3421-3429 | multi_cell | denotes | patients |
| T88 | 3472-3481 | protein_molecule | denotes | IFN alpha |
| T89 | 3518-3526 | protein_complex | denotes | NFkappaB |
| T90 | 3587-3594 | protein_molecule | denotes | TCRzeta |